ReviewExperimental dermatology2025
The Role of ROS-Mediated Mitochondrial Dysfunction in the Development of Malignant Melanoma.
Review in Experimental dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cold atmospheric plasma treated medium (PTM) induce antitumor effects in human ovarian cancer cells.Cancer cell international · 2026Article
- Metabolic Responses of Melanocytes and Melanoma Cells to UVA Radiation and Phytocannabinoids Exposure.Antioxidants (Basel, Switzerland) · 2026Article
- Regulation and Implementation of Apoptosis in Melanoma Tumor Cells withCurrent issues in molecular biology · 2026Review
- The Role of Mitochondrial ROS in Neoplastic Transformations, Progression and Therapeutic Targeting.Oncology research · 2026Review
- The Role of ROS-Mediated Mitochondrial Dysfunction in the Development of Malignant Melanoma.Experimental dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) are critical to cellular metabolism, signal transduction and apoptosis. Recent studies have revealed the dual role of ROS in malignant melanoma pathogenesis and progression, where they can both promote tumour proliferation and metastasis or inhibit tumour growth by inducing apoptosis. Mitochondria, often referred to as the energy factories of cells, are closely involved in ROS generation, and their dysfunction significantly affects cellular homeostasis. This review explores the mechanisms by which ROS-mediated mitochondrial dysfunction contributes to malignant melanoma, focusing on its effects within the tumour microenvironment and its potential as a therapeutic target. Understanding these interactions is essential for developing novel strategies to combat malignant melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.